STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells

Jared Klarquist, Cassandra M. Hennies, Maria A. Lehn, Rachel A. Reboulet, Sonia Feau and Edith M. Janssen

*J Immunol* 2014; 193:6124-6134; Prepublished online 10 November 2014;
doi: 10.4049/jimmunol.1401869
http://www.jimmunol.org/content/193/12/6124

Supplementary Material
http://www.jimmunol.org/content/suppl/2014/11/08/jimmunol.1401869.DCSupplemental

References
This article cites 57 articles, 20 of which you can access for free at:
http://www.jimmunol.org/content/193/12/6124.full#ref-list-1

Subscription
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts

The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852

Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.
STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells

Jared Klarquist,*1 Cassandra M. Hennies,*1 Maria A. Lehn,* Rachel A. Reboulet,* Sonia Feau,† and Edith M. Janssen*

Adaptive immune responses to Ags released by dying cells play a critical role in the development of autoimmunity, allograft rejection, and spontaneous as well as therapy-induced tumor rejection. Although cell death in these situations is considered sterile, various reports have implicated type I IFNs as drivers of the ensuing adaptive immune response to cell-associated Ags. However, the mechanisms that underpin this type I IFN production are poorly defined. In this article, we show that dendritic cells (DCs) can uptake and sense nuclear DNA-associated entities released by dying cells to induce type I IFN. Remarkably, this molecular pathway requires STING, but not TLR or NLR function, and results in the activation of IRF3 in a TBK1-dependent manner. DCs are shown to depend on STING function in vivo to efficiently prime IFN-dependent CD8+ T cell responses to tumor Ags. Furthermore, loss of STING activity in DCs impairs the generation of follicular Th cells and plasma cells, as well as anti-nuclear Abs, in an inducible model of systemic lupus erythematosus. These findings suggest that the STING pathway could be manipulated to enable the rational design of immunotherapies that enhance or diminish antitumor and autoimmune responses, respectively. The Journal of Immunology, 2014, 193: 6124–6134.

The immune system carefully balances its response to dead and dying cells to maintain homeostasis and prevent the development of autoimmunity. Although uptake and clearance of dying cells is generally considered a tolerogenic process, the existence of immunogenic cell death has been well described (1). Depending on the nature of the cell death, dying cells can emit damage-associated molecular patterns (DAMPs) (2) that act as danger signals and increase a dying cell’s immunogenicity. Many of these DAMPs seem to use the sensing and signaling pathways that are normally associated with the recognition and elimination of pathogens. Given the importance of immune responses to cell-associated Ags in autoimmunity, allograft rejection, and tumor rejection, the identification of these DAMPs, their cognate sensors, and their proinflammatory sequelae have become topics of intense research.

Ample studies have implicated type I IFNs in the development or progression of immune responses to self-Ags in autoimmune diseases such as rheumatoid arthritis, type I diabetes mellitus, Sjögren syndrome, and systemic lupus erythematosus (SLE) (3). However, type I IFNs were only recently identified as a crucial mediator in the priming of CD8+ T cells to cell-associated Ags in cancer and cancer treatments. Mice that lack type I IFN sensing, either by genetic IFN receptor (IFNAR) deletion or treatment with blocking Ab, develop more chemically induced tumors and show poorer rejection of transplanted immunogenic tumors than wild-type (WT) mice, highlighting the requirement for type I IFN in spontaneous tumor rejection (4, 5). Additional studies showed that the spontaneous induction of tumor-specific CD8+ T cells in tumor-bearing mice was predominantly mediated by type I IFN sensing in dendritic cells (DCs) (6, 7). A similar role for type I IFN was seen in therapy-induced tumor elimination. Burnett et al. (8) and Kang et al. (9) showed increased intratumoral production of type I IFN upon ablative radiotherapy or chemotherapy. The ablative effect of the therapy was associated with enhanced (cross)priming capacity of tumor-infiltrating DCs and could be abolished by eliminating IFNAR from the hematopoietic compartment. Our previous work, using tumor cell therapy in vaccination and therapeutic settings, showed a comparable dependency of type I IFN in the induction of protective antitumor CD8+ T cell responses (10–12).

Although the general immunostimulatory effects of type I IFN on DCs are well studied, little is known on the cellular source of type I IFN, the type I IFN–inducing ligand, and the receptor–signaling pathways involved in its induction upon the sensing and clearance of dying cells. Our previous work indicated that DCs can produce type I IFN upon phagocytosis of dying cells (10–12). Importantly, DCs from MyD88−/−/TRIF−/− mice double-deficient mice showed normal type I IFN production upon phagocytosis of dying cells, and type I IFN–dependent CD8+ T cell priming to tumor cell vaccines was comparable in WT and MyD88−/−/TRIF−/− mice, indicating that the type I IFN induction requires an unidentified TLR-independent sensing pathway (11).

Using various murine cancer and tumor cell vaccination models and in vitro approaches, we show that the type I IFN production...
upon sensing of dying cells is not only TLR independent, but also RLR independent, and requires STING-IRF3-mediated sensing of apoptotic cell–derived nuclear DNA structures by DCs. The ensuing type I IFN production enhances DC functionality in an autocrine manner, resulting in the increased clonal expansion, polyfunctionality, and memory formation of tumor-specific CD8+ T cells. Importantly, the role of the STING/IRF3/IFNAR nexus was not limited to CD8+ T cell priming or tumor models; elimination of STING or IFNAR significantly impacted the development of CD4+ follicular T h cells (Th9), plasma cells, and anti-nuclear Abs in an inducible model of SLE. Collectively, our results demonstrate that STING/IRF3 sensing of nuclear DNA-derived structures by DCs broadly drives the priming of adaptive immune responses to dying cells.

Materials and Methods

Mice, cells lines, and peptides

Mice were maintained under specific pathogen-free conditions in accordance with Association for Assessment and Accreditation of Laboratory Animal Care International. C57BL/6J, B6.PL-Thy1a/CyJ (B6/CD90.1), B6.SJL.Pepcr-r8 (B6/CD45.1), CD11c–DTR, and B6(Cy–2,Ab1bm12)KhiEg1 mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and H2-Kb+/− mice from Harlan (Indianapolis, IN). IFNAR−/−, Myd88−/−/TRIF−/−, CD11c–DTR–IFNAR−/−, and ActmOVA/H2−K+/− mice were bred in our facility. IRF3−/− and IRF7−/− mice were a gift from Dr. K. Fitzgerald (University of Massachusetts Medical School, Worcester, MA). STING−/− mice a gift from Dr. R. Vance (University of Berkeley, Berkeley, CA), and IPS-1−/− mice a gift from Dr. J. Tschopp (University of Lausanne, Lausanne, Switzerland).

Mixed bone marrow (BM) chimeric mice were generated using donors on different congenic backgrounds in 1:1 ratios. All BM chimeric mice were rested for 12 wk before experiments were started.

Erythrocytes, normoblasts, reticulocytes, and RBCs were generated from B6.PL-CBA (B16-OVA) or B6/129S mice, MEC.B7.SigOVA, Tap-sufficient and -deficient MEFs expressing the human adenovirus type 5 early region 1 (Ad5E1-TAKO, I1.2), and ISRE-L929 IFN reporter cells have been described previously (13–16). Peptides OVA257–264 (SIINFEKL), 5 early region 1 (Ad5E1-TAKO, I1.2), and ISRE-L929 IFN reporter cells were obtained from A&A Laboratories (San Diego, CA).

Cell isolations

T cells, B cells, Mph, and DCs were sorted by flow cytometry using markers TCRβ, CD4, CD8, CD11c, CD11b, CD19, CD45R, and MHC class II as described previously (12). Purity of sorted cells was generally >98% and viability was >97% as determined by 7-AAD staining.

Erythrocytes, normoblasts, reticulocytes, and RBCs were generated using a mouse-adapted protocol for the long-term ex vivo erythroid differentiation of murine colonies described by Gentzert et al. (17) and Konstantinidis et al. (18). In brief, low-density BM cells were cultured in erythropoietin growth medium (StemPro-34 with 2.6% StemPro-34 supplement; Invitrogen), 20% BIT 9500 (Stemcell Technologies), 900 ng/ml ferrous sulfate, 90 ng/ml ferrous nitrate, 10−8 M hydrocortisone, penicillin/streptomycin, l-glutamine, in three subsequent phases. For the proliferative phase (days 1–5), cells were expanded with 100 ng/ml stem cell factor, 5 ng/ml IL-3, and 2 IU/ml human erythropoietin (Amgen). In the differentiation step (days 6–7), the cells were supplemented with only erythropoietin in fibronectin-coated plates. For enucleation (days 8–9), cells were treated with DNAse to eliminate genomic DNA contaminations. Gene expression analysis was performed by quantitative real-time PCR using SYBR Green and primers for β-actin (forward, 5′-TTGCTGACAGGAGTGAAG-3′; reverse, 5′-GATCTGGCCTACG-GAGGAG-3′) and pan IFN-α (forward, 5′-TCTGATGACGAGTGGTTG-3′; reverse, 5′-AGGGCCTCCAGCTTCTGCTG-3′). Samples were treated with DNase to eliminate genomic DNA contaminations. Gene expression analysis was performed using the relative standard curve method and was normalized to Gapdh and β-actin expression.

Cell coculture experiments. Cells were incubated with CellTrace Violet (VT)–labeled irradiated splenocytes (Molecular Probes). After 3 and 16 h, DCs were stained with Abs to CD11c, CD11b, CD80, nuclear dye Draq5, and fixable live/dead staining, and analyzed by ImageStream (Amnis, Seattle, WA). At least 10,000 live events were acquired, and the number and size of phagocytosed particles were determined using the spot counting and spot size features after tight masking on the bright-field image to exclude membrane-associated extracellular particles for each condition as shown before (12, 21). To determine T cell activating capacity, we incubated DCs with irradiated OVA257–264+ cells for 4 h, after which CFSE-labeled purified OT-I CD45.1 CD8+ T cells were added as described previously (11). OT-1 cell proliferation and survival were determined after 7 h by analysis of CFSE dilution together with staining for CD8α, Vγ2, CD45.1, and 7-AAD.

DC signaling studies

Imune coprecipitations. Purified DCs were incubated with irIFR3– or STING-deficient splenocytes. At different time points, DCs were sorted, lysed, precipitated using agaroarse-bound Abs to STING (3337; Cell Signaling) or IRF3 (D83B9; Cell Signaling), and probed for p-IFR3 (4D4G, Cell Signaling), TBK-1 (72B587; Novus Biologicals), p-TBK1 (D52C2; Cell Signaling), STAT6 (9362; Cell Signaling), and IPS1 (77275; Novus Biologicals).

In parallel, VT–labeled irradiated IRF3−−/− splenocytes were cultured with WT and STING−−/− DCs, and analyzed by flow cytometry and Amnis ImageStream upon surface staining with CD11c–Pacific Blue and intracellular staining with Draq5 and p-IFR3 (anti-pS386, 4D4G) combined with anti-rabbit IgG Alexa Fluor 488. Correlations between intensity of phagocytosed particle-based staining and p-IRF3 localization in the nucleus were determined using ImageStream software on CD11c+ DCs. By setting tight masking on the cells to discriminate internalized from bound particles followed by tight masking on the nucleus to determine collateralization of the p-IRF3 staining in the nucleus (12).

In vivo models

Immunizations. Mice were injected s.c. or i.p. with irradiated cells (OVA257–264+ splenocytes, 109–1010 B6-OVA, B16/F0, and 5E1-TAKO, 1–5 × 106). Alternatively, mice received i.v. 2 × 105 purified DCs that had been pulsed with irradiated splenocytes or exposed to irradiated cells in vitro (10–12, 21). For depletion studies, CD11c–DTR mice and mixed BM chimeric mice were treated 24 h before and 24 h after immunization with 4 ng/diphtheria toxin i.p.

Tumor models. For the coryzaoblation model, mice were s.c. injected with 4 × 105 B6-OVA or B16/F0 in PBS. Ten days later, tumors (7–10 mm) were cryoablated using Verruca-Freeze armed with a 6-mm probe (Brymill Cryogenic Systems) (22) for 3 × 25-s cycles. To test long-term tumor protection, we challenged the mice with 3 × 104 B16-OVA or B16/F0 40 d after the ablation of the primary tumor and monitored for tumor growth. In the EL-4–mOVA challenge model, mice were immunized with 105 irradiated OVA-Kb+−+ splenocytes as described earlier and 40 d later challenged with 105 EL-4–mOVA cells s.c.

SLE model. In the SLE model (23), mice of indicated genetic backgrounds received 3 × 106 B6(Cy–2,Ab1bm12)KhiEg1 (bm12) splenocytes i.p. Splenic B and T cell composition B was analyzed by flow after 2 wk. Serum levels of anti-dsDNA IgG, IgG1, and IgG2a were determined by ELISA as previously described (24).

T cell analysis

Unless stated differently, analyses were performed 7 d after immunization. CD8+ T cells were enumerated in spleens and draining lymph nodes using OVA257–264+Kb tetramers (Beckman Coulter) or E1B192–200+Db decamers (Immudex) together with staining for CD8α, CD44, and 7-AAD. In parallel, cytokine production and polyfunctionality was determined directly ex vivo by intracellular cytokine staining after a 5-h stimulation with irradiated B16-OVA cells or by ELISPOT (24) as previously described (24).

In vitro and ex vivo type I IFN analyses were performed by quantitative real-time PCR using SYBR Green and primers for β-actin (forward, 5′-TTGCTGACAGGAGTGAAG-3′; reverse, 5′-GATCTGGCCTACG-GAGGAG-3′) and pan IFN-α (forward, 5′-TCTGATGACGAGTGGTTG-3′; reverse, 5′-AGGGCCTCCAGCTTCTGCTG-3′). Samples were treated with DNase to eliminate genomic DNA contaminations. Gene expression analysis was performed using the relative standard curve method and was normalized to Gapdh and β-actin expression.
Capacity for secondary expansion in vitro was determined by stimulating the splenocytes or purified CD8⁺ T cells on irradiated MEC.B7.SigOVA (OVA-specific) or I1.2 cells (E1B specific) for 6 d and dividing the absolute number of Ag-specific CD8⁺ T cells at the beginning of the culture by the absolute number of Ag-specific CD8⁺ T cells at the end of the culture as described previously (16, 25). In vivo secondary expansion was determined by reinjecting the mice with a 10-fold higher number of irradiated cells than used during immunization. Four days after the secondary challenge, the frequency of Ag-specific CD8⁺ T cells was compared with nonchallenged immunized mice (16).

Results

Protective antitumor immunity requires type I IFN sensing by DCs

We and others recently showed that type I IFN sensing is critical for the induction of protective antitumor responses in various tumor models in both vaccination and therapeutic settings (6–8, 22). Cryoablation of B16-OVA tumors in WT mice resulted in effective priming of OVA₂₅₇₋₂₆₄-specific CD8⁺ T cells that provided protective immunity upon subsequent B16-OVA challenge. In contrast, IFNAR⁻/⁻ mice failed to induce adequate OVA₂₅₇₋₂₆₄-specific CD8⁺ T responses and succumbed upon tumor rechallenge (Fig. 1A, 1B). Similarly, immunization with gamma-irradiated, OVA-expressing Kᵇ⁻/⁻ splenocytes (OVA-Kᵇ⁻/⁻) induced a significantly more robust OVA₂₅₇₋₂₆₄-specific CD8⁺ T cell response

Statistical analyses

Data were analyzed using Prism software (GraphPad Software). Unless stated otherwise, the data are expressed as means ± SEM. Survival responses were analyzed by Kaplan–Meier using a log-rank test. All other data were evaluated using a two-way ANOVA followed by a Dunnett’s test. A p value <0.05 was considered statistically significant.

FIGURE 1. Protective CD8⁺ T cell induction requires IFNAR on DCs. (A) WT and IFNAR⁻/⁻ mice were s.c. injected with B16-OVA tumor cells, and palpable tumors were cryoablated 10 d later. Cryoablated and naive mice were s.c. challenged with B16-OVA 40 d later and survival was monitored (n = 8–10/group). (B) OVA₂₅₇₋₂₆₄–specific CD8⁺ T cell frequency in the spleen 7 d after cryoablation. (C) Mice were immunized with irradiated OVA-Kᵇ⁻/⁻ or Kᵇ⁻/⁻ splenocytes and 40 d later s.c. challenged with EL-4–mOVA cells s.c. (D) Frequency of splenic OVA₂₅₇₋₂₆₄–specific CD8⁺ T cells 7 d after immunization as determined by intracellular cytokine staining for IFN-γ after peptide restimulation and by OVA₂₅₇₋₂₆₄–Kᵇ-tetramer staining. (E) Fold expansion of OVA₂₅₇₋₂₆₄–specific CD8⁺ T cells upon stimulation with OVA₂₅₇₋₂₆₄–expressing cells in vitro. Data of representative experiments (out of three to five) are shown (mean ± SEM, n = 8–10/group, *p < 0.05).
in WT mice than in IFNAR−/− mice (Fig. 1C, 1D). The OVA257−264−specific CD8+ T cells from WT mice, but not IFNAR−/− mice, underwent expansion upon secondary encounter with Ag in vitro and in vivo, and protected mice from EL-4-mOVA challenge in vivo (Fig. 1E, Supplemental Fig. 1A). Importantly, this response was not restricted to OVA or the selected pathways of cell death. Similar results were found when the parental line B16/F10 was used and the response to self-Ag TRP-2 was probed (Supplemental Fig. 1B, 1C). In addition, direct immunization with gamma-irradiated, UV-irradiated, Fas-cross-linked, or etoposide-treated cells showed significantly decreased CD8+ T cell responses in IFNAR−/− mice, illustrating a central role for type I IFN in CD8+ T cell priming to cell-associated Ags in various scenarios of cell death (Fig. 2).

Because nearly all cells express IFNAR, we first used BM chimeras to identify which cells required type I IFN sensing in the CD8+ T cell response to dying cells. BM chimeric mice (WT→IFNAR−/−, WT→WT, IFNAR−/−→WT, IFNAR−/−→IFNAR−/−) demonstrated that type I IFN needed to be sensed by the hematopoietic compartment (Fig. 3A, 3B). Additional studies with WT/IFNAR−/−→WT mixed BM chimeric mice indicated that the diminished CD8+ T cell response could not be attributed to the lack of IFNAR on the CD8+ T cells because IFNAR−/−→CD8+ T cells showed only a marginal decrease in clonal expansion (Fig. 3C). Given the important role of DCs in cross-presentation of cell-associated Ags, we next examined the role of type I IFN sensing on DCs. Mixed BM chimeras were generated in which IFNAR−/− recipients received a combination of WT-CD11c-DTR and IFNAR−/−/CD45.1 BM or IFNAR−/−-CD11c-DTR and WT/CD45.1 BM. In this model, the administration of diphtheria toxin (DT)-treated, CD11c-DTR mice upon s.c. immunization with irradiated cells (Fig. 4D).

Induction of type I IFNs is generally associated with innate sensing of pathogenic danger signals. To identify which innate sensing pathways facilitated the type I IFN production, we tested primary DCs from WT, MyD88−/−/Trif−/−/IPS1−/−, IRF3−/−, IRF7−/− and IRF7−/−/IPS1−/−/MAVS/Cardif, and STING−/−/IRF3−/− deficient mice for their type I IFN production upon culture with dying cells. Type I IFN production was similar in WT, MyD88−/−/Trif−/−/IPS1−/−, and IRF7−/−/IPS1−/−/MAVS/Cardif mice, whereas only nominal IFN production was observed in cultures depleted of DCs (Fig. 4A–C) (11, 12). The in vitro data were supported by our observation that IFN-α mRNA was readily detectable in the draining lymph nodes of control-treated, but not diphtheria toxin (DT)-treated, CD11c-DTR mice upon s.c. immunization with irradiated cells (Fig. 4D).

**FIGURE 2.** Impaired CD8+ T cell priming in IFNAR−/− mice is independent of the method of cell death or cell type. Frequency of splenic Ag-specific CD8+ T cells in WT and IFNAR−/− mice 7 d after s.c. immunization with actmOVA-Kbα−/−, UV-irradiated, Fas-cross-linked, or etoposide-treated cells (which were gamma irradiated [1500 rad], UV irradiated [120 mJ/cm2], or treated with FAS cross-linking Ab [Jo-1, 20 µg/ml; 4 h, 37˚C]), 5E1-TAKO cells (3000 rad, 240 mJ/cm2), or treated with etoposide [10 µM]), or B16-OVA or B16/F10 cells (3000 rad or 240 mJ/cm2). Ag-specific T cell frequencies were determined by intracellular cytokine staining upon incubation with OVA257−264, E1B192−200, TRP-2180−188, or control peptide GP33−41 (white bar, control peptide; black bar, specific peptide). Data in all experiments are expressed as mean ± SEM with n = 5. *p < 0.05.
DCs, indicating that the IFN induction was TLR, RIG-I, and Mda5 independent. In contrast, significant reductions in type I IFN production were seen with DCs deficient in STING and the transcription factor IRF3 even though their subset compositions, maturation status, and phagocytic capacity were similar to WT DCs (Fig. 5A, 5B, and data not shown). Immunoprecipitation and Western blotting studies indicated rapid IRF3 phosphorylation in WT DCs and a significant reduction and delay in IRF3 phosphorylation in STING^-/-^ DCs upon exposure to dying cells (Fig. 5C, 5D). To determine whether the magnitude of the nuclear

**FIGURE 3.** Selective requirement for type I IFN sensing in the DCs. (A) Bone-marrow chimeric mice (WT→IFNAR^-/-^, WT→WT, IFNAR^-/-^→WT, IFNAR^-/-^→IFNAR^-/-^) were immunized i.p. with irradiated 5E1-TAKO cells and the frequency of E1B_192–200-specific CD8^+^ T cells in the spleens was determined 7 d later (white bar, control peptide; black bar, E1B_192–200 peptide). (B) The effect on memory formation using these chimeras was determined by measuring Ag-specific T cell expansion ex vivo. Secondary expansion of E1B_192–200-specific CD8^+^ T cells was calculated by dividing the absolute number of E1B_192–200-specific CD8^+^ T cells at the end of a 6 d culture by the absolute number at the start of the culture. (C) WT/CD90.1 mice were irradiated and reconstituted with WT, IFNAR^-/-^ or a 1:1 ratio of WT(CD45.1):IFNAR^-/-^ (CD45.2) bone-marrow. Mice were i.p. immunized with irradiated 5E1-TAKO cells and the frequency of splenic E1B_192–200-specific CD8^+^ T cells in each graft was determined 7 d later. Data of representative experiments (out of three to five) are shown (mean ± SEM, n = 5/group, *p < 0.05).

**FIGURE 4.** Type I IFN production by DCs in vitro and in vivo. Total and subset-depleted splenocytes (A) or purified cell populations (B) from spleens of naive WT mice were cultured with irradiated OVA-Kb^-/-^ splenocytes, and type I IFN in the supernatant was determined 20 h later (black bars, irradiated cells; white bars, no cells). Data are expressed as mean ± SEM with n = 4. (C) Splenocytes from CD11c-DTR mice (treated with PBS or DT 24 h prior) were isolated and cultured with irradiated OVA-Kb^-/-^ splenocytes. Type I IFN in the supernatant was determined 7 h later. The frequency of splenic E1B_192–200-specific CD8^+^ T cells in each grafted WT compartment was determined 6–8 h later. Representative data of one experiment (out of three to four) are shown (mean ± SEM, n = 5, *p < 0.05).
p-IRF3 signal was associated with the frequency and size of phagocytosed particles, we incubated WT and STING

2

2

DCs with VT-labeled, irradiated IRF3

2

2

splenocytes. Uptake of VT materials was determined 6 h later by flow cytometry. Data are expressed as percentage of DCs that contain VT. Representative data of one experiment (out of three to four) are shown (mean ± SEM, n = 4). (C and D) p-IRF3 kinetics in WT and STING

−/−

DCs upon incubation with irradiated IRF3

−/−

splenocytes. (E) ImageStream images of p-IRF3 nuclear translocation in WT DCs 8 h after incubation with VT-labeled irradiated IRF3

−/−

cells. Original magnification ×60. (F) ImageStream analysis of nuclear p-IRF3 intensity and intensity of cytosolic phagocytosed material in WT and STING

−/−

DCs. Tight masking on the cytosol was done to discriminate between bound and internalized cellular material. At least three experiments were performed with 800–1000 analyzed cells/condition. *p < 0.05

Nuclear DNA-derived structures induce type I IFN production by DCs

We next set out to determine the ligand upstream of STING that was responsible for inducing type I IFN. STING facilitates immune responses to various nucleotide structures, including cytosolic dsDNA, and in some cases dsRNA (26–28). Because dsRNA sensing uses the RIG-I/IPS-1 pathway and IPS1

2

DCs have normal type I IFN production, it is likely that the IFN-inducing species released by dying cells is a DNA-based and not an RNA-based entity. Indeed, addition of DNases, but not RNases, to WT DC/irradiated cell cocultures significantly reduced type I IFN production without affecting uptake of cellular material or responses to non-nucleic TLR ligands (Fig. 6A, Supplemental Fig. 2C, 2D). To more rigorously address the role of DNA complexes in the type I IFN induction, we exploited the process of erythropoiesis where RBC precursors sequentially lose their nuclei, mitochondria, and ribosomes. Timed RBC cultures were sorted, irradiated and treated with thrombospondin-1 (irr/TSP) to induce comparable phosphatidylserine expression on the membrane and facilitate an “apoptotic phenotype” in the non-nucleated cells (Fig. 6B). ImageStream analysis showed comparable uptake of the irr/TSP cell subsets by DCs (Fig. 6C). Nucleated irr/TSP
erythroblasts readily induced type I IFN in DCs, whereas enucleated reticulocytes and RBCs failed to do so (Fig. 6D). These data indicate that the IFN-inducing species is nuclear DNA derived.

STING regulates CD8+ T cell responses to dying cells

Given the importance of STING-mediated DNA sensing in the type I IFN production, we next assessed the relative contribution of STING in the priming of CD8+ T cells to dying cell-associated Ags. WT, MyD88^-/-, IRF3^-/-, IRF7^-/-, and IFNAR^-/- mice showed comparable CD8+ T cell priming as determined by tetramer staining, intracellular cytokine staining, and capacity for secondary expansion upon immunization with irradiated 5E1-TAKO cells (Fig. 7A, 7B). In contrast, IFNAR^-/-, IRF3^-/-, and STING^-/- mice showed significantly reduced CD8+ T cell priming (Fig. 7C, 7D). Moreover, the Ag-specific IFNAR^-/-, IRF3^-/-, and STING^-/- CD8+ T cells displayed less cytokine polyfunctionality and impaired capacity for secondary expansion (Fig. 7E). The defect in CD8+ T priming was fully DC regulated as similar results on CD8+ T cell clonal burst, secondary expansion, and cytokine polyfunctionality were seen when purified cross-priming of CD8+ T cells to cell-associated Ags.

To assess whether STING has a broader role in the priming of adaptive immune responses to dying cells, we assessed the induction of CD4+ T cell and B cell responses in the bm12-cGVHD model where H-2b B6 hosts develop lupus-like disease upon transfer of B6.C-H2bm12 CD4+ T cells (29). Both IFNAR^-/- and STING^-/- mice developed considerably less activated CD4+ T cells and Th than WT recipients upon transfer of bm12 CD4+ T cells (Fig. 8A, 8B). Moreover, both IFNAR^-/- and STING^-/- mice developed considerably less activated B cells, plasma cells, and pathogenic anti-dsDNA IgG2a Abs than WT recipients (Fig. 8A, 8C, 8D). Given that the transferred bm12-CD4+ T cells were IFNAR and STING sufficient, these data further support the role for Ag-presenting, cell-intrinsic STING and IFNAR in the induction of adaptive immune responses to dying cell-derived Ags.

Discussion

Type I IFNs have been implicated as the upstream events precipitating autoimmune disease and a prerequisite for effective antitumor radiotherapy. In this study, we identify DC sensing of cell-derived nuclear DNA entities via the STING/IRF3 pathway as a key component in the early type I IFN response to dying cells. Dying cells can emit a plethora of structurally distinct DAMPs, and it is likely that the molecular pathways involved in the sensing of these DAMPs are equally diverse. Although many DAMPs can contribute to the final adaptive immune response to cell-associated Ags, our data identified type I IFN as the dominant proinflammatory factor and STING/IRF3 signaling as the principle pathway in the initiation of the immune responses to cell-associated Ags.
Ags in our tumor models, as well as the autoimmune responses in our SLE model. Although all nucleated cells can sense type I IFN, and type I IFN has been shown to directly act on T cells, our data indicate that the early STING/IRF3-mediated type I IFN predominantly acts on DCs. Transfer of IFNAR2/2 DCs (pulsed with irradiated cells) into WT recipients resulted in similar deficiencies in CD8+ T cell expansion, functionality, and memory formation as the direct immunization of IFNAR2/2 mice. Moreover, immunization of WT/IFNAR2/2 mixed BM chimeric mice did not show any significant difference in CD8+ T cell clonal expansion or polyfunctionality between the WT and IFNAR2/2 grafts. Importantly, transfer of STING−/− or IRF3−/− DCs into WT recipients resulted in similar defects in CD8+ T cell responses as the transfer of IFNAR−/− DCs. Likewise, STING−/− recipients showed identical reduction in Tfh and plasma cell formation as IFNAR−/− recipients in our SLE model. Together with the observation that STING−/− and IRF3−/− DCs have significantly reduced type I IFN induction upon phagocytosis of dying cells, these data implicate that the STING/IRF3 pathway is the critical component in the type I IFN–dependent T cell priming to cell-associated Ags.

It has been suggested that different types of death may induce different DAMPs. We observed comparable type I IFN induction and STING/IRF3 engagement in DCs upon phagocytosis of cells treated with gamma irradiation, UV irradiation, Fas–cross-linking Ab, or etoposide, suggesting that these different types of cell death generated a similar nuclear DNA-derived DAMP (Supplemental Fig. 2B and data not shown). It is also likely that similar nuclear DNA-associated DAMPs become available in vivo as type I IFN induction, and type I IFN–dependent CD8+ T cell priming was readily observed in WT and MyD88/Trif-deficient mice, but sig-

**FIGURE 7.** STING regulates the CD8+ T cells responses to dying cells in vivo. (A) Mice of indicated strains were immunized with irradiated 5E1-TAKO cells, and the frequency of splenic E1B192–200–specific CD8+ T cells was determined 7 d later (white bar, control peptide; black bar, E1B192–200 peptide). (B) Fold expansion of E1B192–200–specific CD8+ T cells from indicated mouse strains upon culture with E1B192–200–expressing feeder cells in vitro. (C) E1B192–200–specific CD8+ T cell frequency in indicated mouse strains 7 d after immunization with irradiated 5E1-TAKO cells. (D) Secondary expansion of E1B192–200–specific CD8+ T cells in vitro. (E) Ex vivo polyfunctionality of E1B192–200–specific CD8+ T cells from (C) as determined by flow cytometry. (F) Frequency of E1B192–200–specific CD8+ T cells in WT mice 7 d after transfer of indicated DCs pulsed with irradiated 5E1-TAKO cells in vitro. (G) Secondary expansion of E1B192–200–specific CD8+ T cells primed by indicated DCs. (H) Ex vivo polyfunctionality of E1B192–200–specific CD8+ T cells primed by indicated DCs. (I) DCs were purified from WT, IFNAR−/−, and STING−/− mice and exposed to irradiated 5E1-TAKO cells or pulsed with 1 μM E1B192–200 peptide. DCs were repurified and 2 × 105 were injected into WT recipients. Seven days later, the frequency of splenic E1B192–200–specific CD8+ T cells was determined (white bar, control peptide; black bar, E1B192–200 peptide). Representative data of one experiment (out of three to four) are shown (mean ± SEM, n = 5–7, *p < 0.05).
significantly reduced in STING<sup>−/−</sup> and IRF3<sup>−/−</sup> mice upon administration of dying cells (gamma, UV, or FAS treated) or upon in vivo tumor cryoablation (11, 22).

Importantly, the crucial role for type I IFN in the priming of protective adaptive antitumor responses is not restricted to situations where massive tumor cell death occurs, as is the case for radiotherapy, chemotherapy, and cryoablative tumor therapies. Recent publications indicate that spontaneous and limited tumor cell death in tumor-bearing mice also resulted in type I IFN–dependent protective immune responses. Fuertes et al. (7) and Diamond et al. (6) showed spontaneous antitumor CD8<sup>+</sup> T cell induction and tumor rejection in tumor-bearing mice that was critically dependent on type I IFN sensing by cross-priming DCs. In this light, it is interesting to note that STING<sup>−/−</sup> mice, like IFNAR<sup>−/−</sup> mice, develop significantly more lung metastases than WT mice upon i.v. injection of low numbers of untreated B16 melanoma cells, illustrating a role for the STING/IFNAR nexus in the antitumor response when cell death is limited (data not shown).

STING can facilitate innate responses to cytosolic bacterial cyclic dinucleotides (cyclic-di-GMP) (30, 31), dsDNA, and in some cases cytosolic dsRNA (26–28). Our data strongly suggest that the main type I IFN–inducing ligand is a nuclear DNA species. STING-mediated dsRNA sensing requires RNA with 5′-triphosphate groups in combination with the IPS-1/RIG-I pathway. The absence of IPS-1 recruitment to STING in WT DCs upon phagocytosis of cellular materials, as well as the normal type I IFN production and CD8<sup>+</sup> T cell responses in IPS1<sup>−/−</sup> mice, effectively argue against a role for dsRNA sensing in the STING/IFN phenotype. Our hypothesis that the type I IFN–inducing ligand is a DNA structure is strongly supported by our in vitro data that show significantly reduced type I IFN induction upon addition of DNases to the dying cell/DC coculture. Moreover, the use of enucleated cells dramatically reduced type I IFN production and cross-priming by WT DCs in vitro. Importantly, the latter experiment also suggested that mitochondrial or ribosomal nucleotide structures had no notable role in the type I IFN production as reticulocytes, enucleated but still containing mitochondria and ribosomes, failed to induce type I IFN.

Recent studies indicate direct binding of cyclic-di-GMP and cyclic-GMP-AMP (cGAMP) to STING but have not provided evidence for direct dsDNA–STING interactions (32, 33) suggesting the involvement of upstream DNA sensors. Over the last few years, several candidate sensors have been identified, including cGAMP synthase (cGAS), which has been shown to signal through STING via the production of cGAMP (34–37). DExD/H-box protein family member DDX41 and IFI16 (p204) have also been implicated as possible DNA sensors acting through STING, but their precise molecular interactions have not been fully elucidated (38, 39). Currently, these candidate DNA sensors...
are studied in in vitro systems where the DNA is directly delivered into the cytosol via transfection, transduction, or infection pathways. However, for the phagocytosed DNA-derived structures to be sensed by the STING pathway, either its key components should be recruited to the phagosome or the DNA-derived species should escape into the cytosol. Although STING can translocate from the endoplasmic reticulum to the Golgi and autophagosome-like compartments, we and others did not observe STING in phagosomes or phagolysosomes (data not shown) (40–44). However, phagosomal DNA sensing via STING could still be possible by phagosomal recruitment of p204 that has reported migratory capacity or cGAS that produces the highly mobile secondary messenger cGAMP (34, 36, 39). In contrast, phagosomal escape is a well-reported process in cross-presentation where protein structures escape into the cytosol to be processed for presentation in MHC class I (20, 45). The exact mechanism by which proteins escape into the cytosol is not known, but it is strongly associated with alkalization of the phagosome and prevention of phagosomal acidification (20, 45, 46). Consistent with the latter possibility, STING-mediated type I IFN production was strongly associated with inhibition of phagosomal acidification (45); in vitro treatments of DCs with agents that accelerated phagosomal acidification decreased type I IFN production, whereas alkalization or the delay of endosomal acidification significantly enhanced type I IFN production (Supplemental Fig. 3). Moreover, we found that DC populations that have the greatest capacity for cross-presentation and slowest phagosomal acidification rate also produced the most type I IFN upon phagocytosis of dying cells (11, 12, 47, and data not shown).

Although the exact mechanism by which the nuclear DNA–derived structure activates the STING pathway needs further elucidation, our data strongly demonstrate its potently role in antitumor immunity and autoimmunity. Our observations are in line with the findings that mice that lack DNase II, responsible for degradation of nuclear DNA–derived structure activates the STING pathway needs further elucidation, our data strongly demonstrate its potently role in antitumor immunity and autoimmunity. Our observations are in line with the findings that mice that lack DNase II, responsible for degradation of nuclear DNA–derived structure activates the STING pathway.

**References**


pathway.

Zhang, X., J. Wu, F. Du, H. Xu, Z. Chen, C. A. Brautigam, X. Zhang, and
Z. J. Chen. 2014. The cytosolic DNA sensor cGAS forms an oligomeric complex
with DNA and undergoes switch-like conformational changes in the activation

DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic

Unterholzner, L., S. E. Keating, M. Baran, K. A. Horan, S. B. Jensen, S. Sharma,
C. M. Sirois, T. Jin, E. Lata, T. S. Xiao, et al. 2010. IFI16 is an innate immune

ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune

Saitoh, T., N. Fujita, T. Hayashi, K. Takahara, T. Satoh, H. Lee, K. Matsunaga,

Amigorena, S., and A. Savina. 2010. Intracellular mechanisms of antigen cross

Savina, A., A. Peres, I. Cebrian, N. Carmo, C. Moita, N. Hacozen, L. F. Moita,
and S. Amigorena. 2009. The small GTPase Rac2 controls phagosomal alka-
linization and antigen crosspresentation selectively in CD8(+) dendritic cells.


Okabe, Y., T. Sano, and S. Nagata. 2009. Regulation of the innate immune re-

Kitahara, Y., K. Kawane, and S. Nagata. 2010. Interferon-induced TRAIL-
2598.

receptor-independent gene induction program activated by mammalian DNA

Ahn, J. D., Gutman, S. Saijo, and G. N. Barber. 2012. STING manifests self-
19391.

Liu, Y., A. A. Jesus, B. Marrero, D. Yang, S. E. Ramsey, G. A. Monetailegr
Activated STING in a vascular and pulmonary syndrome. Nat. Med. 20: 517–
520.

Ablasser, A., I. Hemmerling, J. L. Schmid-Burgk, R. Behrendt, A. Roers,
and V. Hornung. 2014. TREX1 deficiency triggers cell-autonomous immunity in


Rice, G., G. W. Newman, J. Dean, T. Patrick, R. Parmar, K. Flintoff, P. Robins,
cause familial chilblain lupus and dominant Aicardi-Goutieres syndrome. Am. J.

Namjou, B., P. H. Kothari, J. A. Kelly, S. B. Glenn, J. O. Ojwang, A. Adler,

Yang, Y. G., T. Lindahl, and D. E. Barnes. 2007. Trex1 exonuclease degrades
ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell
131: 873–886.

Lee-Kirsch, M. A., M. Gong, D. Chowdhury, L. Senenko, K. Engel, Y. A. Lee,
encoding the 3’-5’ DNA exonuclease TREX1 are associated with systemic lupus

Abe, J., K. Nakamura, R. Nishikomori, M. Kato, N. Mitsuiki, K. Izawa,
of Aicardi-Goutieres syndrome patients identifies a strong association between
dominant TREX1 mutations and chilblain lesions: Japanese cohort study.

Barzzone, N., S. Monti, S. Mollene, M. Godi, M. Marchini, R. Scorza,
M. G. Danieli, and S. D’Alfonso. 2013. Rare variants in the TREX1 gene and
Figure S1. Compromised CD8+ T cell priming to cell-associated antigens in IFNAR-/- mice.  
A. WT and IFNAR-/- mice were immunized with irradiated OVA-Kb-/- splenocytes (open circles) or irradiated Kb-/- splenocytes (black circles). Forty days after immunization mice were s.c. challenged with EL-4-mOVA and tumor growth was monitored. Data are expressed as mean± s.e.m with indicated N/group. The X-axis depicts the days after tumor challenge.
B. WT and IFNAR-/- mice were s.c. inoculated with B16/F10. After 10 days tumors were cryo-ablated and mice were challenged 40 days later with B16/F10 cells s.c. (n=11-14/group). Survival curve of WT and IFNAR-/- mice upon secondary challenge with B16/F10. C. Frequency of TRP-2180-188 specific splenic T cells as determined by ELISPOT 7 days after cryoablation. Representative data of one experiment (of 3) are shown (mean± s.e.m, n=8-12).
Figure S2. Phagocytosis, IRF3 phosphorylation and type I IFN induction by WT and STING-/- DCs. A. Flow cytometric analysis of phagocytosis and p-IRF3 in WT and STING-/- DCs. Purified WT and STING-/- DCs were cultured with CellTrace Violet-labeled irradiated IRF3-/- cells for 8 hr and phagocytosis and IRF3 phosphorylation was determined by flow cytometry. A representative set of one (out of 4 mice) is shown. B. Similar as in A, frequency of WT and STING-/- DCs with p-IRF3 staining within the DCs population that has phagocytosed CellTrace Violet material. CellTrace Violet cells were treated with gamma irradiation, UV irradiation or etoposide (5mM). C. Purified WT DCs were cultured at 4°C (white bars) and 37°C (black bars) with CellTrace Violet-labeled irradiated splenocytes in the presence or absence of RNAses and DNAses. Uptake of CellTrace Violet materials was determined 6 hr later by flow cytometry. Data is expressed as percentage of DCs that contain CellTrace Violet. D. Type I IFN production by purified WT DCs upon overnight stimulation with LPS in the presence of DNAses/RNAses. Data are expressed as mean±s.e.m with n=4.
Figure S3. Lysosomal acidification rate determines IFN production. A. Type I IFN production by purified WT DCs upon stimulation with irradiated cells in the presence of diphenyliodonium (DPI; acceleration of phagosomal acidification) or inhibitors of lysosomal acidification (Chloroquine and ConB). B. Type I IFN production by purified WT DCs upon overnight stimulation with LPS in the presence of indicated agents. C. Purified WT DCs were cultured at 4°C (white bars) and 37°C (black bars) with CellTrace Violet-labeled irradiated splenocytes in the presence or absence of indicated agents. Uptake of CellTrace Violet materials was determined 6 hr later by flow cytometry. Data are expressed as mean±s.e.m with n=4.